Zacks: Brokerages Anticipate Celcuity Inc. (NASDAQ:CELC) to Post -$0.51 EPS

Wall Street brokerages expect that Celcuity Inc. (NASDAQ:CELCGet Rating) will post ($0.51) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Celcuity’s earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.45). Celcuity reported earnings of ($0.25) per share in the same quarter last year, which would suggest a negative year over year growth rate of 104%. The firm is expected to report its next earnings report after the market closes on Monday, January 1st.

On average, analysts expect that Celcuity will report full-year earnings of ($2.84) per share for the current year, with EPS estimates ranging from ($3.20) to ($2.48). For the next financial year, analysts forecast that the business will post earnings of ($3.24) per share, with EPS estimates ranging from ($3.41) to ($3.07). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Celcuity.

Celcuity (NASDAQ:CELCGet Rating) last announced its quarterly earnings results on Wednesday, March 23rd. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). During the same quarter in the previous year, the company posted ($0.25) earnings per share.

Shares of CELC traded down $0.40 during midday trading on Monday, hitting $5.35. 53,138 shares of the company traded hands, compared to its average volume of 62,656. The stock has a 50-day moving average of $7.76 and a 200-day moving average of $11.37. Celcuity has a one year low of $5.31 and a one year high of $33.01. The firm has a market cap of $79.82 million, a P/E ratio of -2.41 and a beta of 1.64. The company has a debt-to-equity ratio of 0.21, a current ratio of 34.06 and a quick ratio of 34.06.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its holdings in shares of Celcuity by 405.2% during the third quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $33,000 after purchasing an additional 1,471 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Celcuity during the second quarter worth about $41,000. Citigroup Inc. grew its holdings in shares of Celcuity by 678.4% during the third quarter. Citigroup Inc. now owns 2,950 shares of the company’s stock worth $53,000 after purchasing an additional 2,571 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Celcuity by 23.2% during the fourth quarter. California State Teachers Retirement System now owns 5,225 shares of the company’s stock worth $69,000 after purchasing an additional 984 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Celcuity by 291.6% during the third quarter. Barclays PLC now owns 3,951 shares of the company’s stock worth $71,000 after purchasing an additional 2,942 shares in the last quarter. Hedge funds and other institutional investors own 38.30% of the company’s stock.

Celcuity Company Profile (Get Rating)

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

See Also

Get a free copy of the Zacks research report on Celcuity (CELC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.